Episode Details
Back to Episodes
Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar
Season 1
Published 2 years, 4 months ago
Description
Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.
CME information and select publications here